Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
Salomé Paillas, Chee Kin Then, Susan Kilgas, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 107, Iss. 1, pp. 212-221
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 114-131
Open Access | Times Cited: 138
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Flávia Alves Verza, Umashankar Das, Ana Lúcia Fachin, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1664-1664
Open Access | Times Cited: 103
Current and emerging therapies for neuroendocrine prostate cancer
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108255-108255
Closed Access | Times Cited: 41
Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
Alejandra Fernández, Connor O’Leary, Kenneth J. O’Byrne, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 34
Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling
Yu‐Chieh Tsai, Tzu-Yin Wang, Chia‐Lang Hsu, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 9, pp. 1753-1764
Open Access | Times Cited: 15
Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor Romidepsin using Poly-(D,L-lactide-co-glycolide) nanoparticles as a drug carrier
Pinyadapat Aroonthongsawat, Siriphan Manocheewa, Chatchawan Srisawat, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107043-107043
Open Access
Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer
Shannon E. Lynch, Corinne L. Crawford, Hailey Houson, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients
Selina E. Eaton, Justyna Kaczmarek, Daanish Mahmood, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 12, pp. 2087-2098
Open Access | Times Cited: 16
The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer
Jieyu Wang, Fangfang Zhong, Jun Li, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
Costanza Lo Cascio, Tigran Margaryan, Ernesto Luna-Melendez, et al.
JCI Insight (2023) Vol. 8, Iss. 22
Open Access | Times Cited: 8
Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling
Parthasarathy Seshacharyulu, Sushanta Halder, Rama Krishna Nimmakayala, et al.
EBioMedicine (2021) Vol. 75, pp. 103772-103772
Open Access | Times Cited: 19
The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment
Ekta Shirbhate, Preeti Patel, Vijay K. Patel, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2457-2469
Closed Access | Times Cited: 19
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies
Aaron Burmeister, Alexa Stephan, Leandro A. Alves Avelar, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 11, pp. 1674-1688
Open Access | Times Cited: 10
Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives
Linda Silina, Fatlinda Maksut, Isabelle Bernard‐Pierrot, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 14
Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
Jennifer Antrobus, Jason L. Parsons
Radiation (2022) Vol. 2, Iss. 1, pp. 149-167
Open Access | Times Cited: 7
MEK is a promising target in the basal subtype of bladder cancer
Nathan Merrill, Nathalie M. Vandecan, Kathleen C. Day, et al.
Oncotarget (2020) Vol. 11, Iss. 44, pp. 3921-3932
Open Access | Times Cited: 8
Reversing vemurafenib‐resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects
Alessandra Fragale, Emilia Stellacci, Giulia Romagnoli, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 5, pp. 1080-1095
Open Access | Times Cited: 2
The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML
Shohre Karimi Kelaye, Fatemeh Najafi, Bahareh Kazemi, et al.
Clinical & Translational Oncology (2022) Vol. 24, Iss. 7, pp. 1250-1261
Closed Access | Times Cited: 4
Role of epigenetic mechanisms in propagating off-targeted effects following radiation based therapies – A review
Swati Bhat, Vijayta Dani Chadha
Mutation Research/Reviews in Mutation Research (2021) Vol. 787, pp. 108370-108370
Closed Access | Times Cited: 5
Current and Emerging Therapies for Neuroendocrine Prostate Cancer
Tanya Stoyanova, Busola R. Alabi, Shiqin Liu
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 3
Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
Dafeng Guo, Yu Yu, Binyu Long, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2512-2529
Open Access | Times Cited: 3
Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization
Patrick J. Lawrence, Benjamin Burns, Xia Ning
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells
Alain Chebly, Martina Prochazkova‐Carlotti, Yamina Idrissi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 3
Singlet Anticancer Therapy Through Epi-Weapons Histone Deacetylase Inhibitors and Its Shortcomings
Shabir Ahmad Ganai
(2020), pp. 173-201
Closed Access | Times Cited: 1
Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
Costanza Lo Cascio, Tigran Margaryan, Ernesto Luna Melendez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top